… Molnupiravir-nirmatrelvir/ritonavir was more effective in vitro … In a case series of
immunocompromised patients, the addition … Treatment algorithms differed between the four …

… modified intention-to-treat population, participants receiving molnupiravir had a lower risk of
… 709 participants) in the molnupiravir group as compared with 9.7% (68 of 699 participants) …

… has been shown to be effective in treating COVID-19. Remdesivir and molnupiravir target
RNA-dependent RNA polymerase (RdRp), while nirmatrelvir targets 3 chymotrypsin-like …

… hypersensitivity reaction (2 treated with molnupiravir and 1 treated with nirmatrelvir/ritonavir). …
We thank all the patients and staff from the Infectious Diseases Unit for participating in this …

… We randomized 149 participants with 116 included in the … placebo-controlled trial of
molnupiravir reported an approximate 30… Finally, we did not include severely …

… -free oral treatment against COVID-19 in immunosuppressed patients taking …
immunocompromised participants in a post hoc analysis from the MOVE-OUT trial, molnupiravir …

… of action, molnupiravir induces a number of genetic mutations after treatment; however, it has
… In the present study, nine patients also received molnupiravir, but only three showed new …

… A total of 78 of 13 795 participants (0.6%) in the molnupiravir … that molnupiravir and
nirmatrelvir–ritonavir treatments were … /ritonavir in hospitalized immunocompromised patients has …

… Since there was no contact with any of the participants, and due to its exempt status, the …
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-…

… A716V was absent in Usual Care but present at <10% allele frequency during or just after
treatment in a further six molnupiravir-treated participants, none of whom had detectable viral …